MedTech Terms
    The authoritative reference
    All terms

    In-House IVDs (Article 5(5))

    Devices manufactured and used within a single EU health institution under conditions in IVDR Article 5(5).

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed July 25, 2026

    Definition

    Article 5(5) exempts devices manufactured and used exclusively within health institutions established in the Union from most IVDR requirements, provided conditions are met: an appropriate quality management system, justification that patient needs cannot be met by an equivalent CE-marked device, documentation on manufacturing and performance, and public declaration and reporting to the competent authority.

    What this means in practice

    In-house diagnostics (also known as laboratory-developed tests or LDTs in EU practice) are a major route for niche and rapidly evolving assays. Transition provisions extended key Article 5(5) documentation deadlines to 2028 and 2030 for high-risk classes, but the basic conditions apply now.
    Common pitfalls
    • Assuming the exemption covers cross-institution networks. It applies to a single health institution.
    • Overlooking the requirement to justify that no equivalent CE-marked device meets the need.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Primary references

    3 sources
    Link health: 2 verified 1 unchecked· last checked 2026-06-20
    EUR-Lex·1MDCG·1IMDRF·1
    1. 1
      Regulation (EU) 2017/746, Article 5(5)
      Verified
      EUR-Lexeur-lex.europa.eu
    2. 2
      MDCG 2023-1 Article 5(5) Guidance
      Unchecked
      MDCGhealth.ec.europa.eu
    3. 3
      IMDRF Documents
      Verified
      IMDRFimdrf.org

    Inline markers like [1] jump to the matching reference above.